Tekmira reports on protection against deadly Ebola virus

Tekmira Pharmaceuticals (TSX:TKM) has published a series of studies in The Lancet demonstrating the ability of an RNA-interference therapeutic using Tekmira’s SNALP lipid nanoparticle delivery technology to protect non-human primates from Ebola virus, a highly contagious and lethal human infectious disease. “These very striking data are the first demonstration that RNAi is efficacious in an [...]

Cormark upgrades Paladin to top pick

Cormark Securities has upgraded Paladin Labs (TSX:PLB) to “top pick” with a new price target of $30 from “buy” and $24.50 on the back of another strong quarter that beat its estimates for revenue, EBITDA and earnings.  The stock closed at $25.45 on Thursday. Analyst David Dean writes that the company’s first quarter performance is [...]

Cormark ups Cardiome price target

Cormark Securities has raised its price target on “buy-rated” Cardiome Pharma (TSX:COM; NASDAQ:CRME) to $10.50 from $7.50, citing a positive outlook from several catalysts expected this year.  The stock closed at $8.28 on Tuesday. According to analyst David Dean, those catalysts included European approval in mid-2010 of the IV version of Cardiome’s vernakalant drug to [...]

Cormark ups Transition price target 52%

Cormark Securities raised its target price on “buy-rated” Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to $8 from $5.25, saying it believes Irish partner Elan is likely to move Transition’s ELND005 drug forward into a Phase 3 clinical trial in Alzheimer’s disease.  The stock closed at $3.50 on the TSX Friday. An imbalance of deaths in an ongoing [...]

Cormark raises QLT price target

On the heels of QLT (NASDAQ:QLTI; TSX:QLT) reaching a 52-week high of $5.45 (U.S.) on Wednesday, Cormark Securities raised its price target to $6.50 from $5.35, maintaining a “buy” rating on the stock. In a new report, analyst David Dean writes that QLT expects to report data this year from two clinical programs, which “do [...]

Tekmira’s leading RNAi platform ready for prime time

As a global leader in the emerging field of RNA interference (RNAi), which holds the potential of revolutionizing medicine with new therapeutics, upstart Tekmira Pharmaceuticals (TSX:TKM) is at the precipice of confirming that the highly touted science works in humans. “We really are at the crux,” CEO Dr. Mark Murray says in an exclusive interview [...]